Kurv Yield Premium Strategy Tesla (TSLA) ETF TSLP 深 沪
等待开盘 11-04 09:30:00 美东时间
26.33
+0.630
+2.45%
华盛通- 最 高26.52
- 今 开25.595
- 成交量 2.86万股
- 最 低 25.595
- 昨 收 25.70
- 总市值 2843.64万
- 52周最高 26.5395
- 市盈率 静 --
- 换手率 2.65%
- 52周最低 12.15
- 委 比 -81.82%
- 总股本 108.00万
- 历史最高 26.5395
- 量 比 2.18
- 振 幅 3.60%
- 历史最低 4.5023
- 每 手 1
- 风险率 3.41%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Celldex Releases Phase 1 Results For Its Bispecific Antibody CDX-622 Showing Drug Was Well Tolerated, Showed Favorable Pharmacokinetics, And Led To Rapid, Sustained Reductions In Serum Tryptase, Confirming Effective Mast Cell Inhibition
Celldex (NASDAQ:CLDX) announced today positive data from the ongoing Phase 1 study of CDX-622, a novel bispecific antibody that targets two non-redundant, complementary pathways implicated in inflammation and
10-31 04:14
Amgen Announces FDA Approval Of TEZSPIRE For Chronic Rhinosinusitis With Nasal Polyps In Patients Aged 12 And Older, Expands Use To Second Epithelial-Driven Disease
Approval Broadens Indication for TEZSPIRE to a Second Disease Characterized by Epithelial-Driven Inflammation
10-18 04:02
荃信生物-B午前涨超7% 公司自免单抗管线产品布局丰富
荃信生物-B（02509）午前股价上涨7.04%，现报29.20港元，成交额1549.89万港元。 天风证券发布研报指出，2024年中国自身免疫性疾病药...
10-16 11:48
中邮证券：首予信达生物“买入”评级 内生收入与利润双高增
中邮证券发布研报称，首次覆盖信达生物（01801），给予“买入”评级，预计公司2025-2027年归母净利润9.8/15.8/32.5亿元，对应PE为16...
10-10 15:03
BD不BD，给个痛快吧
本文来自格隆汇专栏：阿基米德Biotech BD预期已形成堰塞湖。 恒生生物科技指数（HSHKBIO）在节日期间上涨3.7%，重燃创新药二次行情的希望，但在节后...
10-10 08:16
Upstream Bio Highlights New Respiratory Drug Verekitug With Trial Data
Upstream Bio, Inc. (NASDAQ:UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today presented structural and mechanistic data showing
09-30 16:26
天风证券：首予荃信生物-B“买入”评级 目标价40.25港元
天风证券发布研报称，首次覆盖荃信生物-B（02509），给予“买入”评级，预计公司2025-2027年营业收入分别为3.22/4.41/5.93亿元人民币...
09-30 15:33
赛诺菲(SNY.US)TSLP/IL-13双抗启动COPD II/III期临床
9月24日，全球临床试验收录网站显示，赛诺菲(SNY.US)的TSLP/IL-13双抗Lunsekimig(SAR443765)推进至II/III期阶段。
09-26 09:05
Nurix And Gilead Advance IRAK4 Degrader GS-6791 Into Clinical Trials After Preclinical Results In Skin Disease
Nurix Therapeutics, Inc. (NASDAQ:NRIX) today announced the presentation of preclinical data from GS-6791/NX-0479, a novel IRAK4 protein degrader discovered as part of the company's ongoing research collaboration with
09-17 19:10
